When will Biogen finally pull the trigger on a blockbuster M&A deal?
Now that Gilead $GILD, Celgene $CELG and even Sanofi $SNY have pulled off some major league M&A deals, all eyes are on Biogen $BIIB to finally step up and do something…big.
What we got yesterday was a small preclinical deal of no great consequence, a mere appetizer compared to the binge deal analysts have been dreaming about. So you can imagine what the first question was about when the analysts got their shot during the Q4 call on Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
